On August 19, Moderna, Inc. rose 8.74% in pre-market trading, trading at $71.04/share, with turnover of $2.6748 million.

Multiple catalysts are driving the rally. Merck and Moderna jointly announced that their pivotal Phase 3 clinical trial Interpath-001 achieved positive results, demonstrating a substantial reduction in the risk of disease recurrence or death for patients with completely resected Stage IIB-IV melanoma compared to standard adjuvant therapy. Simultaneously, the company confirmed that its first mRNA flu vaccine mFLUSIVA, which received FDA approval earlier this month for adults aged 50 and above, will begin retail distribution in coming weeks to cover the respiratory virus season. mFLUSIVA represents Moderna's fourth FDA-approved product in the US and makes the company the first to bring mRNA technology into the influenza market. Additionally, the receipt of an initial $178.4 million payment from the Arbutus settlement has further strengthened the company's cash position, creating a convergence of positive developments supporting the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)